<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="1"><Row><ArmCount>1+</ArmCount><ProtocolAcronym>COPE</ProtocolAcronym><ProtocolTitle>Benidipine-based Comparison of Angiotensin Receptors, Beta-blockers, or Thiazide Diuretics in Hypertensive Patients</ProtocolTitle><Sponsor>COPE Trial Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79942"></Trial><Drug id="56641">benidipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>3293</Patients><Biomarkers>Blood pressure; Estimated glomerular filtration rate</Biomarkers><Condition>Cardiovascular disease</Condition><Controls></Controls><EnrollmentCount>3501</EnrollmentCount><Interventions>angiotensin receptor blockers; benidipine; benidipine + angiotensin receptor blockers or beta-blockers or thiazide diuretics; beta-blockers; thiazide diuretics</Interventions><Reference>COPE; NCT00135551; UMIN000001152; copeadministrator</Reference></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>